Clinical trials Brief October 2, 2026, 4:59 AM ET

Results posted for Atacicept study in IgA nephropathy

Results for this study were first posted on ClinicalTrials.gov on October 1, 2026. The study, a Phase 3, randomized, double-blinded, placebo-controlled trial (NCT04716231), enrolled 428 participants and began on June 29, 2023.

Primary source

ClinicalTrials.gov results record, October 1, 2026

Atacicept in Subjects With IgA Nephropathy

Read the source: Atacicept in Subjects With IgA Nephropathy clinicaltrials.gov

By The Priority Review desk. Machine-summarized from the source above; not independently reported. How we use automation